JP2018076350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018076350A5 JP2018076350A5 JP2017243830A JP2017243830A JP2018076350A5 JP 2018076350 A5 JP2018076350 A5 JP 2018076350A5 JP 2017243830 A JP2017243830 A JP 2017243830A JP 2017243830 A JP2017243830 A JP 2017243830A JP 2018076350 A5 JP2018076350 A5 JP 2018076350A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- cancer
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 45
- 239000000203 mixture Substances 0.000 claims 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 229920005862 polyol Polymers 0.000 claims 9
- 150000003077 polyols Chemical class 0.000 claims 9
- 238000002360 preparation method Methods 0.000 claims 9
- 206010064930 age-related macular degeneration Diseases 0.000 claims 8
- 208000002780 macular degeneration Diseases 0.000 claims 8
- 238000001542 size-exclusion chromatography Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 5
- 239000000600 sorbitol Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001155 isoelectric focusing Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697111P | 2012-09-05 | 2012-09-05 | |
| US61/697,111 | 2012-09-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531196A Division JP2015532657A (ja) | 2012-09-05 | 2013-09-05 | 抗体製剤及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018223128A Division JP6602446B2 (ja) | 2012-09-05 | 2018-11-29 | 抗体製剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018076350A JP2018076350A (ja) | 2018-05-17 |
| JP2018076350A5 true JP2018076350A5 (https=) | 2018-10-11 |
| JP6445671B2 JP6445671B2 (ja) | 2018-12-26 |
Family
ID=50237600
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531196A Pending JP2015532657A (ja) | 2012-09-05 | 2013-09-05 | 抗体製剤及びその使用 |
| JP2017243830A Expired - Fee Related JP6445671B2 (ja) | 2012-09-05 | 2017-12-20 | 抗体製剤及びその使用 |
| JP2018223128A Expired - Fee Related JP6602446B2 (ja) | 2012-09-05 | 2018-11-29 | 抗体製剤及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531196A Pending JP2015532657A (ja) | 2012-09-05 | 2013-09-05 | 抗体製剤及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018223128A Expired - Fee Related JP6602446B2 (ja) | 2012-09-05 | 2018-11-29 | 抗体製剤及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10195281B2 (https=) |
| EP (1) | EP2892559A4 (https=) |
| JP (3) | JP2015532657A (https=) |
| KR (2) | KR101820582B1 (https=) |
| CN (2) | CN108785669A (https=) |
| AU (2) | AU2013312536B2 (https=) |
| BR (1) | BR112015004875A2 (https=) |
| CA (1) | CA2883343A1 (https=) |
| EA (1) | EA029214B1 (https=) |
| GE (1) | GEP201706789B (https=) |
| HK (1) | HK1210714A1 (https=) |
| IL (1) | IL237287A0 (https=) |
| MX (1) | MX368996B (https=) |
| MY (1) | MY180157A (https=) |
| NZ (1) | NZ705109A (https=) |
| PH (1) | PH12015500480B1 (https=) |
| SG (2) | SG11201501659SA (https=) |
| UA (1) | UA115789C2 (https=) |
| WO (1) | WO2014039682A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CN106928359B (zh) * | 2015-12-30 | 2020-10-13 | 广西医科大学 | 一种CD105纳米抗体Nb59 |
| CN106928355B (zh) * | 2015-12-30 | 2020-09-29 | 广西医科大学 | 一种CD105纳米抗体Nb184 |
| CN106478820A (zh) * | 2016-10-10 | 2017-03-08 | 米度（南京）生物技术有限公司 | 一种肝癌pet诊断示踪剂及其制备方法与用途 |
| JP7536640B2 (ja) * | 2017-11-17 | 2024-08-20 | アムジエン・インコーポレーテツド | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
| BR112020015052A2 (pt) * | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| CN112717129A (zh) * | 2019-10-14 | 2021-04-30 | 百奥泰生物制药股份有限公司 | 抗vegf抗体制剂 |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| WO2021257947A1 (en) | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| JP2026505800A (ja) | 2023-02-03 | 2026-02-18 | ジェンザイム・コーポレーション | Ｈｓｃ特異的抗体結合脂質ナノ粒子及びその使用 |
| WO2025217334A1 (en) * | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US928641A (en) | 1908-10-09 | 1909-07-20 | Levi E Edmunds | Clasp for pilings. |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz, Joseph R. | Phasenmodulationsenergieübertragungsfluoroimmunassay |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| ES2169864T3 (es) | 1996-05-31 | 2002-07-16 | Health Research Inc | Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. |
| US6190660B1 (en) | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| US5796097A (en) | 1997-03-05 | 1998-08-18 | California Lightwave Laboratories, Inc. | Chemical sensor and method |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE10013850A1 (de) * | 2000-03-15 | 2001-09-20 | Schering Ag | Gasgefüllte Mikrokapseln enthaltend funktionalisiertes Polyalkylcyanacrylat, sowie Verfahren zu deren Herstellung |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| MXPA03007316A (es) | 2001-02-19 | 2003-12-04 | Merck Patent Gmbh | Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida. |
| WO2002072824A2 (en) | 2001-02-20 | 2002-09-19 | Bayer Aktiengesellschaft | Human transient receptor potential channel protein. |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030003048A1 (en) | 2001-04-26 | 2003-01-02 | Chun Li | Diagnostic imaging compositions, their methods of synthesis and use |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| WO2003028840A2 (en) | 2001-09-27 | 2003-04-10 | Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| US7115716B2 (en) | 2001-11-19 | 2006-10-03 | Eli Lilly And Company | Tumor specific monoclonal antibodies |
| AU2003211990A1 (en) * | 2002-02-14 | 2003-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
| WO2003086289A2 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US7754884B2 (en) | 2005-01-03 | 2010-07-13 | Vanderbilt University | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging |
| US7097836B1 (en) | 2002-10-23 | 2006-08-29 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| US7691374B2 (en) | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US7120987B2 (en) | 2003-08-05 | 2006-10-17 | Avery Dennison Corporation | Method of making RFID device |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2006226060A1 (en) | 2005-03-25 | 2006-09-28 | Glycart Biotechnology Ag | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| AR057807A1 (es) | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
| US20070092577A1 (en) | 2005-10-03 | 2007-04-26 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| US20100129379A1 (en) * | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| AU2007301599B2 (en) | 2006-09-28 | 2013-01-10 | Merck Serono S.A. | Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| MX2009008132A (es) | 2007-02-01 | 2009-08-12 | Genentech Inc | Terapia de combinacion con inhibidores de angiogenesis. |
| DK2170938T3 (da) | 2007-06-06 | 2012-07-16 | Res Dev Foundation | RTEF-1-varianter samt deres anvendelse til inhibering af angiogenese |
| CA2696049A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| JP5461402B2 (ja) | 2007-09-14 | 2014-04-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換三環式化合物およびその使用方法 |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| EP2235189A1 (en) | 2008-01-14 | 2010-10-06 | Genentech, Inc. | Methods for inhibiting angiogenesis using egfl8 antagonists |
| PE20141062A1 (es) | 2008-08-29 | 2014-09-19 | Bayer Ip Gmbh | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) |
| CA2737667A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Targeted binding agents directed to cd105 and uses thereof |
| US8699361B2 (en) | 2008-09-30 | 2014-04-15 | Qualcomm Incorporated | Out-of-synchronization handling method and apparatus |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AR076640A1 (es) | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
| US20180057602A1 (en) | 2009-08-17 | 2018-03-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EA025367B1 (ru) | 2009-08-17 | 2016-12-30 | Тракон Фармасьютикалз, Инк. | Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf |
| CN103108658B (zh) | 2010-07-02 | 2015-08-19 | 米迪缪尼有限公司 | 抗体制剂 |
| DK2699590T3 (en) | 2011-04-20 | 2019-05-06 | Acceleron Pharma Inc | ENDOGLIN POLYPEPTIDES AND APPLICATIONS THEREOF |
| EP2739645B1 (en) | 2011-08-01 | 2018-12-19 | Tufts Medical Center, Inc. | Endoglin-specific antibody for use in a method of treating heart failure and related conditions |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| WO2015042269A1 (en) | 2013-09-20 | 2015-03-26 | Tufts Medical Center, Inc. | Methods and compositions for reducing cardiac damage and other conditions |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
-
2013
- 2013-05-09 UA UAA201501709A patent/UA115789C2/uk unknown
- 2013-09-05 CN CN201810659773.9A patent/CN108785669A/zh active Pending
- 2013-09-05 EA EA201590412A patent/EA029214B1/ru not_active IP Right Cessation
- 2013-09-05 NZ NZ705109A patent/NZ705109A/en not_active IP Right Cessation
- 2013-09-05 SG SG11201501659SA patent/SG11201501659SA/en unknown
- 2013-09-05 KR KR1020157008487A patent/KR101820582B1/ko not_active Expired - Fee Related
- 2013-09-05 GE GEAP201313760A patent/GEP201706789B/en unknown
- 2013-09-05 BR BR112015004875A patent/BR112015004875A2/pt not_active Application Discontinuation
- 2013-09-05 EP EP13834890.9A patent/EP2892559A4/en not_active Withdrawn
- 2013-09-05 KR KR1020187001035A patent/KR20180007014A/ko not_active Abandoned
- 2013-09-05 AU AU2013312536A patent/AU2013312536B2/en not_active Ceased
- 2013-09-05 US US14/421,108 patent/US10195281B2/en active Active - Reinstated
- 2013-09-05 JP JP2015531196A patent/JP2015532657A/ja active Pending
- 2013-09-05 HK HK15111622.6A patent/HK1210714A1/xx unknown
- 2013-09-05 SG SG10201705070PA patent/SG10201705070PA/en unknown
- 2013-09-05 MY MYPI2015000556A patent/MY180157A/en unknown
- 2013-09-05 MX MX2015002840A patent/MX368996B/es active IP Right Grant
- 2013-09-05 CN CN201380046405.2A patent/CN104684580A/zh active Pending
- 2013-09-05 CA CA2883343A patent/CA2883343A1/en not_active Abandoned
- 2013-09-05 WO PCT/US2013/058265 patent/WO2014039682A1/en not_active Ceased
-
2015
- 2015-02-17 IL IL237287A patent/IL237287A0/en unknown
- 2015-03-05 PH PH12015500480A patent/PH12015500480B1/en unknown
-
2017
- 2017-12-20 JP JP2017243830A patent/JP6445671B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 AU AU2018204044A patent/AU2018204044A1/en not_active Abandoned
- 2018-07-13 US US16/034,658 patent/US20180311359A1/en not_active Abandoned
- 2018-11-29 JP JP2018223128A patent/JP6602446B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018076350A5 (https=) | ||
| JP7262440B2 (ja) | 抗ｃｄ４７抗体及びその使用 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| TWI640537B (zh) | ＰＤＧＦ受體β結合多肽 | |
| JP2025098019A (ja) | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 | |
| JP2016528882A5 (https=) | ||
| JP2014522843A5 (https=) | ||
| JP2020138981A5 (https=) | ||
| JP2016515511A5 (https=) | ||
| JP2014514346A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| AU2019232762A1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2017537090A5 (https=) | ||
| JP2020518598A5 (https=) | ||
| JP2021504372A5 (https=) | ||
| EP3672987B1 (en) | Anti-apelin antibodies and uses thereof | |
| JP2017160208A5 (https=) | ||
| JP2017507652A5 (https=) | ||
| JP2017514461A5 (https=) | ||
| JP2020506924A5 (https=) | ||
| JP2016533335A5 (https=) | ||
| JP2016534052A5 (https=) | ||
| JP2021514379A5 (https=) | ||
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| JP2019509311A5 (https=) |